Bone Biologics Priced An Underwritten Public Offering Of 2.54M Shares At $1.97 Per Share, For Aggregate Gross Proceeds Of Approximately $5M
Portfolio Pulse from Benzinga Newsdesk
Bone Biologics has priced an underwritten public offering of 2.54 million shares at $1.97 per share, raising approximately $5 million in aggregate gross proceeds.
June 15, 2023 | 7:31 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bone Biologics' underwritten public offering of 2.54 million shares at $1.97 per share will raise approximately $5 million in gross proceeds.
Bone Biologics' public offering will raise approximately $5 million in gross proceeds, which can be used for the company's growth and development. However, the short-term impact on the stock price is uncertain as it depends on market reaction to the offering and the company's use of the proceeds.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100